Detection of colorectal cancer by serum and tissue protein profiling: A prospective study in a population at risk

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 375-385

  Engwegen, Judith Y M N ^a,e   Depla, Annekatrien C T M ^a   Smits, Marianne E ^b   Cats, Annemieke ^b   Tuynman, Henriëtte ^a   van Heukelem, Henk A ^a   Snel, Pleun ^a   Meuleman, Wouter ^b   Wessels, Lodewyk F ^b   Schellens, Jan H M ^c,d   Beijnen, Jos H ^c,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e Sittard Geleen Heerlen   (Netherlands)

Author keywords

Biomarkers; Colorectal cancer; SELDI TOF MS; Validation

Indexed keywords

APOLIPOPROTEIN C1; PLASMA PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER MORTALITY; CANCER STAGING; COLON POLYPOSIS; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; EARLY DIAGNOSIS; EUROPE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; PATIENT CODING; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECTUM POLYP; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 50049123030     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s790     Document Type: Article

References (26)

1. Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M. and Boyle, P. 2007. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 18(3):581-92.
2. Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., Turnbull, B.A. and Ross, M.E. 2004. The Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med., 351(26):2704-14.
3. Duffy, M.J. 2001. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?. Clin. Chem., 47(4):624-30.
4. Ahlquist, D.A., Wieand, H.S., Moertel, C.G., McGill, D.B., Loprinzi, C.L., O'Connell, M.J. et al. 1993. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA, 269(10):1262-7.
5. Greenberg, P.D., Bertario, L., Gnauck, R., Kronborg, O., Hardcastle, J.D., Epstein, M.S. et al. 2000. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am. J. Gastroenterol., 95(5):1331-8.
6. Van't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Mao, M. et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871)530-6.
7. Engwegen, JYMN., Gast, MCW., Schellens, JHM. and Beijnen, J.H. 2006. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci., 27(5):251-9.
8. Chen, Yd., Zheng, S., Yu, Jk. and Hu, X. 2004. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res., 10(24):8380-5.
9. Yu, J.K., Chen, Y.D. and Zheng, S. 2004. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol., 10(21):3127-31.
10. Engwegen, JYMN., Helgason, H.H., Cats, A., Harris, N., Bonfrer, JMG., Schellens, JHM. et al. 2006. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol., 12(10):1536-44.
11. Ward, D.G., Suggett, N., Cheng, Y., Wei, W., Johnson, H., Billingham, L.J. et al. 2006. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer, 94(12):1898-905.
12. Liu, X.P., Shon, J., Li, Z.F., Yan, L. and Gu, J. 2006. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest., 24(8):747-53.
13. Habermann, J.K., Roblick, U.J., Luke, B.T., Prieto, D.A., Finlay, W.J., Podust, V.N. et al. 2006. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology, 131(4):1020-9.
14. Schmitt, M., Mengele, K., Schueren, E, Sweep, F.C., Foekens. J.A., Brunner, N. et al. 2007. European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur. J. Cancer, 43(5):835-44.
15. Wessels, L.F., Reinders, M.J., Hart, A.A., Veenman, C.J., Dai, H., He, Y.D. et al. 2005. A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics, 21(19):3755-62.
16. Engwegen, JYMN., Alberts, M., Knol, J.C., Jimenez, J.R., Depla, ACTM, Tuynman, H. et al. 2008. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics Clin. Appl., 2(6):936-45.
17. Jong, M.C., Hofker, M.H. and Havekes, L.M. 1999. Role of ApoCs in lipoprotein metabolism: Functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb. Vasc. Biol., 19(3):472-84.
18. Göbel, T., Vorderwülbecke, S., Hauck, K., Fey, H., Haussinger, D. and Erhardt, A. 2006. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J. Gastroenterol., 12(47):7604-12.
19. Pang, R.T., Poon, T.C., Chan, K.C., Lee, N.L., Chin, R.W., Tong, Y.K. et al. 2006. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin. Chem., 52(3):421-9.
20. Tachibana, M., Ohkura, Y., Kobayashi, Y., Sakamoto, H., Tanaka, Y., Watanabe, J. et al. 2003. Expression of apolipoprotein A1 in colonic adenocarcinoma. Anticancer Res., 23(5b):4161-7.
21. Hyman, N.H., Anderson, P. and Blasyk, H. 2004. Hyperplastic polyposis and the risk of colorectal cancer. Dis. Colon Rectum, 47(12):2101-4.
22. Melle, C., Ernst, G., Schimmel, B., Bleul, A., Thieme, H., Kauffmann, R. et al. 2005. Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology, 129(1):66-73.
23. Albrethsen, J., Bogebo, R., Gammeltoft, S., Olsen, J., Winther, B. and Raskov, H. 2005. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer, 5(1):8.
24. Albrethsen, J., Moller, C.H., Olsen, J., Raskov, H. and Gammeltoft, S. 2006. Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur. J. Cancer, 42(17):3057-64.
25. Melle, C., Bogumil, R., Ernst, G., Schimmel, B., Bleul, A. and Von Eggeling, F. 2006. Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics, 6(8):2600-8.
26. Melle, C., Ernst, G., Schimmel, B., Bleul, A., Mothes, H., Kaufmann, R. et al. 2006. Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int. J. Oncol., 28(1):195-200.